Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 2819 - Provider product page
- Provider
- Cell Signaling Technology, Inc
- Proper citation
- Cell Signaling Technology Cat#2819, RRID:AB_10692515
- Product name
- Bim Antibody
- Antibody type
- Polyclonal
- Reactivity
- Human, Mouse, Rat, Simian
- Host
- Rabbit
- Storage
- -20°C
Submitted references Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
Bcl-2 allows effector and memory CD8+ T cells to tolerate higher expression of Bim.
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide.
Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD
PloS one 2011;6(9):e25351
PloS one 2011;6(9):e25351
Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.
Tagoug I, Sauty De Chalon A, Dumontet C
PloS one 2011;6(7):e22641
PloS one 2011;6(7):e22641
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA
Cancer discovery 2011 Sep;1(4):352-65
Cancer discovery 2011 Sep;1(4):352-65
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW
Proceedings of the National Academy of Sciences of the United States of America 2011 Oct 18;108(42):17432-7
Proceedings of the National Academy of Sciences of the United States of America 2011 Oct 18;108(42):17432-7
Bcl-2 allows effector and memory CD8+ T cells to tolerate higher expression of Bim.
Kurtulus S, Tripathi P, Moreno-Fernandez ME, Sholl A, Katz JD, Grimes HL, Hildeman DA
Journal of immunology (Baltimore, Md. : 1950) 2011 May 15;186(10):5729-37
Journal of immunology (Baltimore, Md. : 1950) 2011 May 15;186(10):5729-37
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Jane EP, Premkumar DR, Pollack IF
Molecular cancer therapeutics 2011 Jan;10(1):198-208
Molecular cancer therapeutics 2011 Jan;10(1):198-208
Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide.
Widenmaier SB, Ao Z, Kim SJ, Warnock G, McIntosh CH
The Journal of biological chemistry 2009 Oct 30;284(44):30372-82
The Journal of biological chemistry 2009 Oct 30;284(44):30372-82
No comments: Submit comment
No validations: Submit validation data